Leadership
The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.
Nicolas Poirier, CEO of French biotech OSE Immunotherapeutics, spoke with In Vivo about the company's anti-IL-7R antibody, lusvertikimab, on the heels of impressive ulcerative colitis data presented at the 2025 European Crohn's and Colitis Organization meeting.
Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.
In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.
The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
Top 30 leaders: see the list of industry influencers highlighted in the sixth edition of In Vivo's Rising Leaders series.
Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.
Antag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.
Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.
Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.
Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.
A perspective on global healthcare trends and UK opportunities from Yogan Patel, head of life sciences at chartered accountancy MHA, a member firm of Baker Tilley International.
With British Science Week upon us, how are UK life science firms faring, what’s the outlook for the future, and how can the environment be improved to better foster innovation – and make it pay?
Rentschler Biopharma CEO Benedikt von Braunmühl tells In Vivo about the CDMO's strategic decision to exit the cell and gene therapy manufacturing space.
Twenty executives in the biopharma industry outline their expectations for key trends and developments this year. A selection of commentary from a broad industry survey by Scrip.
Neutrophil Extracellular Traps are a double-edged sword in the immune system, capable of both defending against pathogens and driving inflammatory diseases. Their complex role in health and disease is being approached by innovative researchers and biotechs, who are working to harness their power while mitigating their harmful effects.
Steven Damon, Micron Biomedical CEO, discusses the promising future of Micron’s microneedle technology, which allows for painless vaccine delivery through pressing a small patch onto the skin.
This is the second of a two-part profile of Hans Clevers, head of Pharma Research and Early Development at Roche, in which he talks about his vision for the future of personalized medicine.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.